TY - JOUR
T1 - Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders
T2 - a double blinded, randomized controlled trial
AU - Gillingham, Melanie B.
AU - Heitner, Stephen
AU - Martin, Julie
AU - Rose, Sarah
AU - Goldstein, Amy
AU - El-Gharbawy, Areeg Hassan
AU - Deward, Stephanie
AU - Lasarev, Michael R.
AU - Pollaro, Jim
AU - DeLany, James P.
AU - Burchill, Luke
AU - Goodpaster, Bret
AU - Shoemaker, James
AU - Matern, Dietrich
AU - Harding, Cary O.
AU - Vockley, Jerry
N1 - Funding Information:
Funding This study was funded by the Food & Drug Administration, Orphan Drug Development Program, Grant FD038950. Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR000128 and UL1TR001857. JV was supported in part by NIH grant R01 DK78775.
Funding Information:
Acknowledgements This study was funded by the Food & Drug Administration, Orphan Drug Development Program, Grant FD038950. The authors sincerely thank all of the subjects who participated in this trial. Research reported in this publication was also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers UL1TR000128 and UL1TR001857. JV was supported in part by NIH grant R01 DK78775. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2017, SSIEM.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Background: Observational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium-chain triglyceride (MCT) treatment of long-chain fatty acid oxidation disorders (LC-FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven-carbon fatty acid triglyceride, to trioctanoin (C8), an eight-carbon fatty acid triglyceride, in patients with LC-FAODs. Methods: A double blinded, randomized controlled trial of 32 subjects with LC-FAODs (carnitine palmitoyltransferase-2, very long-chain acylCoA dehydrogenase, trifunctional protein or long-chain 3-hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis. Results: Patients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate-intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups. Conclusions: C7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC-FAODs. Clinical Trial Registration: Clinicaltrials.gov NCT01379625.
AB - Background: Observational reports suggest that supplementation that increases citric acid cycle intermediates via anaplerosis may have therapeutic advantages over traditional medium-chain triglyceride (MCT) treatment of long-chain fatty acid oxidation disorders (LC-FAODs) but controlled trials have not been reported. The goal of our study was to compare the effects of triheptanoin (C7), an anaplerotic seven-carbon fatty acid triglyceride, to trioctanoin (C8), an eight-carbon fatty acid triglyceride, in patients with LC-FAODs. Methods: A double blinded, randomized controlled trial of 32 subjects with LC-FAODs (carnitine palmitoyltransferase-2, very long-chain acylCoA dehydrogenase, trifunctional protein or long-chain 3-hydroxy acylCoA dehydrogenase deficiencies) who were randomly assigned a diet containing 20% of their total daily energy from either C7 or C8 for 4 months was conducted. Primary outcomes included changes in total energy expenditure (TEE), cardiac function by echocardiogram, exercise tolerance, and phosphocreatine recovery following acute exercise. Secondary outcomes included body composition, blood biomarkers, and adverse events, including incidence of rhabdomyolysis. Results: Patients in the C7 group increased left ventricular (LV) ejection fraction by 7.4% (p = 0.046) while experiencing a 20% (p = 0.041) decrease in LV wall mass on their resting echocardiogram. They also required a lower heart rate for the same amount of work during a moderate-intensity exercise stress test when compared to patients taking C8. There was no difference in TEE, phosphocreatine recovery, body composition, incidence of rhabdomyolysis, or any secondary outcome measures between the groups. Conclusions: C7 improved LV ejection fraction and reduced LV mass at rest, as well as lowering heart rate during exercise among patients with LC-FAODs. Clinical Trial Registration: Clinicaltrials.gov NCT01379625.
UR - http://www.scopus.com/inward/record.url?scp=85028812824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028812824&partnerID=8YFLogxK
U2 - 10.1007/s10545-017-0085-8
DO - 10.1007/s10545-017-0085-8
M3 - Article
C2 - 28871440
AN - SCOPUS:85028812824
SN - 0141-8955
VL - 40
SP - 831
EP - 843
JO - Journal of Inherited Metabolic Disease
JF - Journal of Inherited Metabolic Disease
IS - 6
ER -